Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pigmented ciliary epithelium (None)
- Target
- None
- Molecular classification
- Other (cellular layer, not a typical molecular target class), Sometimes categorized as a specialized epithelial cell barrier
01
Overview
The pigmented ciliary epithelium is the outer layer of the bilayered ciliary epithelium lining the ciliary body of the eye[1][3][7]. Composed of cuboidal cells packed with melanin granules, this layer plays a supportive role in absorbing stray light within the eye and contributes to the blood-aqueous barrier. It is developmentally continuous with the retinal pigment epithelium and the pigmented layer of the iris[3][7]. While it participates in ion and solute transport in conjunction with the nonpigmented ciliary epithelium and contains gap junctions for intercellular communication, its principal function is light absorption rather than aqueous humor secretion[3]. The pigmented ciliary epithelium is not a direct molecular or pharmacological target in current therapeutic strategies[1][3][7].
- Other names
- PECiliary epithelium, pigmented layerOuter ciliary epithelium
02
Mechanism of action
None specific. Drugs for glaucoma reduce aqueous humor production or increase outflow via mechanisms not restricted to this pigmented layer[5].
03
Biological functions
Light absorption to prevent scatter within the eyeForms part of the blood-aqueous barrierSupports ion transport cooperation with nonpigmented ciliary epitheliumMinor contribution to aqueous humor production (mainly by nonpigmented layer)Connective continuity with adjacent pigmented epithelia of iris and retina
04
Disease associations
Other (no primary roles, but can be involved indirectly in conditions affecting the ciliary body/uveal tract or when altered by disease, e.g., pigment dispersion glaucoma, uveitis)
05
Safety considerations
None specific to this cell layer. General risks involve trauma, inflammation (uveitis), or pigment release in disease, but not targeted safety concerns in therapeutics.
06
Interacting drugs
None specifically. Drugs targeting ciliary body function (e.g., carbonic anhydrase inhibitors, beta-blockers for glaucoma) do not act specifically on the pigmented ciliary epithelium but rather on fluid production physiology involving the whole epithelium or ciliary processes[5].
07
Biomarkers
None specific. Neither the pigmented ciliary epithelium nor its products serve as direct, recognized biomarkers for disease or therapy monitoring.
Beyond the preview
Go deeper on Pigmented ciliary epithelium (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pigmented ciliary epithelium (None).